[{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Vitronectin","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Sanford Burnham Prebys Medical Discovery Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Sanford Burnham Prebys Medical Discovery Institute \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sanford Burnham Prebys Medical Discovery Institute \/ Not Applicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"The University of Pittsburgh School of Medicine \/ Astellas Pharma"},{"orgOrder":0,"company":"Synedgen","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Synedgen \/ National Eye Institute","highestDevelopmentStatusID":"2","companyTruncated":"Synedgen \/ National Eye Institute"},{"orgOrder":0,"company":"SemaThera Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Semaphorin-3A","graph1":"Ophthalmology","graph2":"Discovery","graph3":"SemaThera Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"SemaThera Inc \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"SemaThera Inc \/ Roche"},{"orgOrder":0,"company":"Mosaic Biosciences","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Complement","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Mosaic Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Mosaic Biosciences \/ Ocular Therapeutix","highestDevelopmentStatusID":"2","companyTruncated":"Mosaic Biosciences \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"ATPGroup","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Non-viral Based Gene Therapy","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intergalactic Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Intergalactic Therapeutics \/ ATP","highestDevelopmentStatusID":"2","companyTruncated":"Intergalactic Therapeutics \/ ATP"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"SPVN50","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ SparingVision","highestDevelopmentStatusID":"2","companyTruncated":"Intellia Therapeutics \/ SparingVision"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Kriya Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Kriya Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Kriya Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"engEx-AAV","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Codiak BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Toolgen","sponsor":"mCureX","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"TGT-101","moa":"VEGF","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Toolgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Toolgen \/ mCureX","highestDevelopmentStatusID":"2","companyTruncated":"Toolgen \/ mCureX"},{"orgOrder":0,"company":"VivaVision","sponsor":"Everads Therapy","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"VivaVision \/ Everads Therapy","highestDevelopmentStatusID":"2","companyTruncated":"VivaVision \/ Everads Therapy"},{"orgOrder":0,"company":"Avista Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Avista Therapeutics","amount2":1.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":1.01,"dosageForm":"","sponsorNew":"Avista Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Avista Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Capsida","amount2":0.67000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Capsida \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Capsida \/ AbbVie"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"SpliceBio","amount2":0.22,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0.22,"dosageForm":"","sponsorNew":"SpliceBio \/ Spark Therapeutics, Inc","highestDevelopmentStatusID":"2","companyTruncated":"SpliceBio \/ Spark Therapeutics, Inc"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RTx-021","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Ray Therapeutics \/ CIRM","highestDevelopmentStatusID":"2","companyTruncated":"Ray Therapeutics \/ CIRM"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Wide-ranging A*STAR and SERI partnership will accelerate the development of novel developmental gene therapy candidates in the areas of ophthalmology and oncology.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 05, 2024

                          Lead Product(s) : Gene Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : A*STAR

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Antibody-based Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : GC Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The funding will be used to support development of RTx-021, an optogenetic therapy for the treatment of geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD).

                          Brand Name : RTx-021

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 13, 2023

                          Lead Product(s) : RTx-021

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : CIRM

                          Deal Size : $4.0 million

                          Deal Type : Funding

                          blank

                          04

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Under the agreement, Spark secures exclusive worldwide rights to SpliceBio's proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal disease.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 17, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : Spark Therapeutics, Inc

                          Deal Size : $216.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Under the terms of the collaboration, AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : $70.0 million

                          February 23, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : AbbVie Inc

                          Deal Size : $665.0 million

                          Deal Type : Collaboration

                          blank

                          06

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Under the terms of collaboration agreement, VivaVision and Everads will jointly conduct pre-clinical research activities, in order to identify lead candidates for future clinical development and commercialization.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 06, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : Everads Therapy

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The partnership aims to apply Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology to develop intravitreal AAV capsids matching a capsid profile defined by Roche.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : $7.5 million

                          July 19, 2022

                          Lead Product(s) : AAV-based Gene Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : $1,007.5 million

                          Deal Type : Partnership

                          blank

                          08

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed